A Modified Nucleoside O6-methyl-2'-deoxyguanosine-5'-Triphosphate Exhibits Anti-Glioblastoma Activity in a Caspase-Independent Manner
Zi-Hui Wang,Jin Li,Qian Liu,Jian-Chang Qian,Qing-Qing Li,Qing-Yu Wang,Lv-Tao Zeng,Si-Jia Li,Xin Gao,Jia-Xin Pan,Xu-Fan Gao,Kun Wu,Guo-Xin Hu,Tomoo Iwakuma,Jian-Ping Cai
DOI: https://doi.org/10.1016/j.phrs.2023.106990
IF: 10.334
2023-11-01
Pharmacological Research
Abstract:Resistance to temozolomide (TMZ), the frontline chemotherapeutic agent for glioblastoma (GBM), has emerged as a formidable obstacle, underscoring the imperative to identify alternative therapeutic strategies to improve patient outcomes. In this study, we comprehensively evaluated a novel agent, O6-methyl-2'-deoxyguanosine-5'-triphosphate (O6-methyl-dGTP) for its anti-GBM activity both in vitro and in vivo. Notably, O6-methyl-dGTP exhibited pronounced cytotoxicity against GBM cells, including those resistant to TMZ and overexpressing O6-methylguanine-DNA methyltransferase (MGMT). Mechanistic investigations revealed that O6-methyl-dGTP could be incorporated into genomic DNA, disrupting nucleotide pools balance, and inducing replication stress, resulting in S-phase arrest and DNA damage. The compound exerted its anti-tumor properties through the activation of AIF-mediated apoptosis and the parthanatos pathway. In vivo studies using U251 and Ln229 cell xenografts supported the robust tumor-inhibitory capacity of O6-methyl-dGTP. In an orthotopic transplantation model with U87MG cells, O6-methyl-dGTP showcased marginally superior tumor-suppressive activity compared to TMZ. In summary, our research, for the first time, underscores the potential of O6-methyl-dGTP as an effective candidate against GBM, laying a robust scientific groundwork for its potential clinical adoption in GBM treatment regimens.
pharmacology & pharmacy